Tiefenbach J, Magomedova L, Liu J, Reunov A, Tsai R, Eappen N, et al. Idebenone and coenzyme Q10 are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases. Dis Model Mech. 2018;11: pubmed publisher

Wang H, Xu Z, Wu A, Dong Y, Zhang Y, Yue Y, et al. 2-deoxy-D-glucose enhances anesthetic effects in mice. Anesth Analg. 2015;120:312-9 pubmed publisher

Fiebiger S, Bros H, Grobosch T, Janssen A, Chanvillard C, Paul F, et al. The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse. J Neuroimmunol. 2013;262:66-71 pubmed publisher

Parkinson M, Schulz J, Giunti P. Co-enzyme Q10 and idebenone use in Friedreich's ataxia. J Neurochem. 2013;126 Suppl 1:125-41 pubmed publisher

Sadun A, La Morgia C, Carelli V. Mitochondrial optic neuropathies: our travels from bench to bedside and back again. Clin Exp Ophthalmol. 2013;41:702-12 pubmed publisher

Klopstock T, Metz G, Yu Wai Man P, Buchner B, Gallenmüller C, Bailie M, et al. Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy. Brain. 2013;136:e230 pubmed publisher

Barboni P, Valentino M, La Morgia C, Carbonelli M, Savini G, De Negri A, et al. Idebenone treatment in patients with OPA1-mutant dominant optic atrophy. Brain. 2013;136:e231 pubmed publisher

Goldschmidt R, Arce P, Khdour O, Collin V, Dey S, Jaruvangsanti J, et al. Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases. Bioorg Med Chem. 2013;21:969-78 pubmed publisher

Rudolph G, Dimitriadis K, Büchner B, Heck S, Al Tamami J, Seidensticker F, et al. Effects of idebenone on color vision in patients with leber hereditary optic neuropathy. J Neuroophthalmol. 2013;33:30-6 pubmed publisher

Bababeygy S, Wang M, Khaderi K, Sadun A. Visual improvement with the use of idebenone in the treatment of Wolfram syndrome. J Neuroophthalmol. 2012;32:386-9 pubmed publisher

Carbone C, Pignatello R, Musumeci T, Puglisi G. Chemical and technological delivery systems for idebenone: a review of literature production. Expert Opin Drug Deliv. 2012;9:1377-92 pubmed publisher

Heitz F, Erb M, Anklin C, Robay D, Pernet V, Gueven N. Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy. PLoS ONE. 2012;7:e45182 pubmed publisher

Gamondi O, Chapela S, Nievas I, Burgos I, Alonso M, Stella C. Idebenone treatment mediates the effect of menadione oxidative stress damage in Saccharomyces cerevisiae. Drug Metab Lett. 2012;6:120-3 pubmed

Ojano Dirain C, Antonelli P. Prevention of gentamicin-induced apoptosis with the mitochondria-targeted antioxidant mitoquinone. Laryngoscope. 2012;122:2543-8 pubmed publisher

Kiblboeck D, Braeuer Mocker M, Siostrzonek P, Reisinger J. A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest. BMJ Case Rep. 2012;2012: pubmed publisher

Montenegro L, Ottimo S, Puglisi G, Castelli F, Sarpietro M. Idebenone loaded solid lipid nanoparticles interact with biomembrane models: calorimetric evidence. Mol Pharm. 2012;9:2534-41 pubmed publisher

Nohara Y, Suzuki J, Yamazaki Y, Kubo H. Determination of idebenone in plasma by HPLC with post-column fluorescence derivatization using 2-cyanoacetamide. Chem Pharm Bull (Tokyo). 2012;60:598-602 pubmed

Montenegro L, Sinico C, Castangia I, Carbone C, Puglisi G. Idebenone-loaded solid lipid nanoparticles for drug delivery to the skin: in vitro evaluation. Int J Pharm. 2012;434:169-74 pubmed publisher

Erb M, Hoffmann Enger B, Deppe H, Soeberdt M, Haefeli R, Rummey C, et al. Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I. PLoS ONE. 2012;7:e36153 pubmed publisher

Montenegro L, Trapani A, Latrofa A, Puglisi G. In vitro evaluation on a model of blood brain barrier of idebenone-loaded solid lipid nanoparticles. J Nanosci Nanotechnol. 2012;12:330-7 pubmed

Kearney M, Orrell R, Fahey M, Pandolfo M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev. 2012;:CD007791 pubmed publisher

Rauchova H, Vokurkova M, Drahota Z. Idebenone-induced recovery of glycerol-3-phosphate and succinate oxidation inhibited by digitonin. Physiol Res. 2012;61:259-65 pubmed

Koopman W, Willems P, Smeitink J. Monogenic mitochondrial disorders. N Engl J Med. 2012;366:1132-41 pubmed publisher

Mariotti C, Fancellu R, Caldarazzo S, Nanetti L, Di Bella D, Plumari M, et al. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord. 2012;27:446-9 pubmed publisher

Anheim M, Mariani L, Calvas P, Cheuret E, Zagnoli F, Odent S, et al. Exonic deletions of FXN and early-onset Friedreich ataxia. Arch Neurol. 2012;69:912-6 pubmed

Sabet Peyman E, Khaderi K, Sadun A. Is Leber hereditary optic neuropathy treatable? Encouraging results with idebenone in both prospective and retrospective trials and an illustrative case. J Neuroophthalmol. 2012;32:54-7 pubmed publisher

Li B, Ge Z. Nanostructured lipid carriers improve skin permeation and chemical stability of idebenone. AAPS PharmSciTech. 2012;13:276-83 pubmed publisher

Gerhardt E, Graber S, Szego E, Moisoi N, Martins L, Outeiro T, et al. Idebenone and resveratrol extend lifespan and improve motor function of HtrA2 knockout mice. PLoS ONE. 2011;6:e28855 pubmed publisher

Giorgio V, Petronilli V, Ghelli A, Carelli V, Rugolo M, Lenaz G, et al. The effects of idebenone on mitochondrial bioenergetics. Biochim Biophys Acta. 2012;1817:363-9 pubmed publisher

Newman N. Treatment of Leber hereditary optic neuropathy. Brain. 2011;134:2447-50 pubmed publisher

Becker C, Bray French K, Drewe J. Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol. 2010;6:1437-44 pubmed publisher

Schulz J, Di Prospero N, Fischbeck K. Clinical experience with high-dose idebenone in Friedreich ataxia. J Neurol. 2009;256 Suppl 1:42-5 pubmed publisher

Meier T, Buyse G. Idebenone: an emerging therapy for Friedreich ataxia. J Neurol. 2009;256 Suppl 1:25-30 pubmed publisher

Tonon C, Lodi R. Idebenone in Friedreich's ataxia. Expert Opin Pharmacother. 2008;9:2327-37 pubmed

Farris P. Idebenone, green tea, and Coffeeberry extract: new and innovative antioxidants. Dermatol Ther. 2007;20:322-9 pubmed

Damulin I. [The use of idebenone (noben) in neurological practice]. Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106:66-71 pubmed

Geromel V, Darin N, Chretien D, Benit P, DeLonlay P, Rotig A, et al. Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol Genet Metab. 2002;77:21-30 pubmed

. Idebenone - monograph. Altern Med Rev. 2001;6:83-6 pubmed

Gillis J, Benefield P, McTavish D. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging. 1994;5:133-52 pubmed

Suno M, Nagaoka A. Inhibition of brain mitochondrial swelling by idebenone. Arch Gerontol Geriatr. 1989;8:299-305 pubmed

Morimoto H. [Synthesis and biochemical actions of idebenone and related compounds. Ubiquinone and related compounds, XL]. Naturwissenschaften. 1989;76:200-5 pubmed